Emerging Paradigms in ALK-Positive NSCLC

Introduction

ALK TKIs Available/Ongoing Investigation

Relative Efficacy of ALTA vs Comparators

Safety Profile of ALK Inhibitors in the Post Crizotinib Setting

Early Onset Pulmonary Events With Brigatinib

Classical EOPE Timing of Onset and Offset

Summary of Second-Line Discussion

Summary of Second-Line Discussion (cont)

ALEX: Alectinib vs Crizotinib as First-Line Therapy

ALTA-1L: Brigatinib vs Crizotinib in the First-Line

Alectinib: PFS by CNS Metastatic Status

Intracranial PFS by IRC

Median Duration of Follow Up Only 9 to 11 Months in ALTA-1L to Date - Extracranial PFS Differences yet to Fully Realize

Summary of First-Line Data

Abbreviations